Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

Table 2

Number of adverse CV events prevented with ezetimibe when added over and above statins (data from the IMPROVE-IT study).

Event type	Numbers halted
Combination of CVD, nonfatal MI,UA, revascularization, and nonfatal stroke	11
Nonfatal MI	5
Nonfatal stroke	2
Revascularization	4

For 100 patients treated for 10 years (CVD- cardiovascular death; UA- unstable angina; MI- myocardial infarction).